Home » Topics » Disease categories and therapies » Immune

Immune
RSS

ABX-CBL promising for the management of GVHD according to phase II trial

Oct. 9, 2001

Good stability, favorable pharmacokinetics determined for LJP-920

Oct. 3, 2001

Enrollment completed for phase I/II StreptAvax trial

Sep. 28, 2001

Potential therapy for GVHD continues in late-stage clinical development

Sep. 27, 2001

Second orphan drug designation received for orBec in GVHD

Sep. 27, 2001

Human Genome Sciences receives FDA approval to begin clinical trials of BLyS

Sep. 21, 2001

Inhibitex enters into partnership with Wyeth Lederle Vaccines

Sep. 19, 2001

Recent patent covers hydroxamic acid-based inhibitors of sCD23

Sep. 17, 2001

Maxygen and InterMune to develop next-generation interferon gamma products

Sep. 10, 2001

Advanced Viral Research given clearance to move Product R into phase I clinical trials

Sep. 6, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...